sales@contrivedatuminsights.com
CDI - Contrive Datum Insights
Press ReleaseConsumer Goods & Retail

Single Use Bioprocessing Systems Market Projected at USD 80.3 billion by 2034 on 11.72% Annual Growth

42% of 2025 revenue sits in North America, and 13.3% growth in Single-use bioreactors leads the product type axis.

PUNE, INDIA — 24 SEPTEMBER 2026 — CONTRIVE DATUM INSIGHTS

From USD 29.5 billion in 2025 to USD 80.3 billion in 2034, a 11.72% compound annual rate.

42% of 2025 revenue (USD 12.39 billion) is generated in North America.

Fastest growth: Single-use bioreactors at 13.3% a year.

32% of 2025 revenue sits in Single-use media bags and containers, the largest product type line.

Contrive Datum Insights has published "Single Use Bioprocessing Systems Market Size, Share & Industry Analysis, By Product type (Single-use media bags and containers, Single-use assemblies, Single-use bioreactors, Disposable mixers, Other products), Application (Monoclonal antibodies (mAbs), Vaccines, Cell therapies, Other products), Work flow (Upstream Bioprocessing, Fermentation, Downstream Bioprocessing), Method (Filtration, Storage, Cell culture, Mixing, Purification), End-user (Biopharmaceutical Manufacturers, CMOs & CROs, In-house Manufacturers, Academic & Clinical Research Institutes), and Regional Forecast, 2026-2034". The study sizes the global single use bioprocessing systems market at USD 29.5 billion in 2025 and projects growth from USD 33.1 billion in 2026 to USD 80.3 billion by 2034, a compound annual growth rate of 11.72% across the forecast period.

Single-use bioprocessing systems are pre-sterilized, disposable bags, assemblies, bioreactor vessels, mixers and connectors used in place of fixed stainless steel equipment across the manufacture of biologic drugs. They are supplied as bags and containers for fluid storage and transport, tubing and connector assemblies, stirred or wave-mixed disposable bioreactors, and disposable mixing systems, each discarded and replaced between production batches rather than cleaned and revalidated. Buyers are biopharmaceutical manufacturers, contract manufacturing and research organizations, in-house production units and academic or clinical research institutes producing monoclonal antibodies, vaccines and cell therapies.

Growth in monoclonal antibody and biologics manufacturing capacity

Growth in monoclonal antibody and biologics manufacturing capacity is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.72% a year, the product type lines exposed to it move fastest: Single-use bioreactors compounds at 13.3%, taking its share of revenue from 30% to 34% and its value from USD 8.85 billion to USD 27.3 billion.

On the upside, the study's bull case assumes biologics pipeline approvals and CMO capacity expansions run ahead of the base case, accelerating conversion from stainless steel to single-use systems across all regions, which would take 2034 revenue to USD 94.75 billion against the USD 80.3 billion base case.

Against that, biologics approval timelines slow and capital spending on new biomanufacturing capacity is deferred, keeping stainless steel systems in service longer than the base case assumes. On that reading 2034 revenue stops at USD 68.26 billion. The weight of the problem sits in Single-use media bags and containers: 32% of 2025 revenue growing at 10.48%, well under the market's 11.72%.

Single-use media bags and containers Scale Against Single-use bioreactors Momentum

The product type axis, not the regional one, is what divides the field. Single-use media bags and containers is the volume position, 32% of 2025 revenue at USD 9.44 billion, holding 29% through 2034, and it is defended by scale. Single-use bioreactors is the growth position at 13.3%, and it is open. Strength in one does not carry into the other.

Further Report Findings

SegmentLed 2025 byShare & valueFastest-growing
ApplicationMonoclonal antibodies (mAbs)48% · USD 14.16 billionCell therapies 16.92%
Work flowUpstream Bioprocessing42% · USD 12.39 billion—
MethodCell culture28% · USD 8.26 billion—
End-userBiopharmaceutical Manufacturers50% · USD 14.75 billionCMOs & CROs 13.33%
  • North America was the largest region in 2025, holding 42% of global revenue at USD 12.39 billion and reaching USD 29.71 billion by 2034.
  • Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 29% in 2034, with revenue growing from USD 6.49 billion to USD 23.29 billion.
  • Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3.5% by 2034.
  • By product type, the largest line in 2025 was Single-use media bags and containers, at 32% of revenue and USD 9.44 billion.
  • Single-use bioreactors is projected to grow at 13.3% over the forecast period, the fastest of any product type line.
  • The United States is the largest single country market at USD 10.53 billion in 2025, 35.69% of global revenue.

Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by product type, and by application, work flow, method and end-user. The headline total carries bear, base and bull cases at USD 68.26 billion and USD 94.75 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.

Regions Covered
North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa
About Contrive Datum Insights

Contrive Datum Insights is a global market intelligence and consulting firm working across investment, information technology, healthcare and manufacturing markets. Every market we publish is sized twice — once top-down from the leading players and once bottom-up from the addressable base — and validated by primary interview. More about CDI.

Asia Pacific
Kunjir Shyama Prestine, Sr. no. 174/1
Jagtap Diary Road, Pimple Saudagar
Pune 411017, India
+91 983 481 6757
United States
21C2 Lakeshore Dr.
Farmington, CT 06032
United States
+1 215 297 4078